CSL regards stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.
CSL’s Executive Sustainability Committee has overall responsibility for the materiality process and executes a global materiality assessment on a biennial basis. In 2021/22, we concluded our fifth assessment and followed the Global Reporting Initiative (GRI) standards of sustainability context, materiality, completeness and stakeholder inclusiveness through our process of identification, review and prioritisation.
Support for the UN Sustainable Development (SD) Goals
Across our value chain CSL’s activities support the achievement of the United Nations Sustainable Development goals.
View a summary of our Key Performance Data in the following areas: Our People, Innovation, Safety and Quality, Economic Contribution, Community, and Environment, in section 13 of our 2021/22 Annual Report.